CTRI/2010/091/001135进行中（未招募）2 期
A Multi Centre, Pilot Phase II Trial Assessing The Efficacy And Safety Of Bevacizumab + Gemcitabine + Carboplatin As First Line Treatment For Patients Diagnosed With Triple Negative Metastatic Breast Cancer.
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •* Female patients, >/= 18 years of age
- •* Metastatic breast cancer
- •* Estrogen receptor- , progesterone- and HER2-negative disease
- •* Treatment-naïve for metastatic breast cancer
- •* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •* Adequate hematological, renal and liver function
排除标准
- •Prior first line treatment for metastatic breast cancer
- •CNS metastasis
- •Uncontrolled hypertension ( 170/95 mmHg)
- •Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
- •History of other malignant disease within past 3 years, except for curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
- •Prior therapy with gemcitabine or carboplatin in the metastatic setting. Patients having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented 6 months after the last exposure to the drug(s)
- •Requirement of chronic use of immunosuppressive agents
- •HIV, hepatitis B or hepatitis C infection
研究者
相似试验
未知
2 期
A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant GliomaMalignant gliomaJPRN-jRCT2080220811Chugai Pharmaceutical Co., Ltd.31
进行中（未招募）
1 期
Phase 2 study of lenvatinib plus pembrolizumab for advanced melanoma in anti-PD-1/L1-exposed participantsMedDRA version: 20.0 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864Advanced melanomaEUCTR2018-002518-10-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Phase 2 study of lenvatinib plus pembrolizumab for advanced melanoma in anti-PD-1/L1-exposed participantsAdvanced melanomaEUCTR2018-002518-10-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
已完成
2 期
The safety of Cpn10 in patients with multiple sclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12606000037505CBio Limited50
进行中（未招募）
1 期
Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal FailureShort Bowel Syndrome-associated Intestinal Failure (SBS-IF)MedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-000176-11-DEHanmi Pharmaceutical Co., Ltd.18